0001626971 false 0001626971 2023-06-15 2023-06-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 15, 2023

 

CORVUS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-37719   46-4670809

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification Number)

 

863 Mitten Road, Suite 102

Burlingame, CA 94010

(Address of principal executive offices, including Zip Code)

 

 

Registrant’s telephone number, including area code: (650) 900-4520

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: 

 

     
Title of each class Trading symbol(s) Name of each exchange on which registered
Common Stock, Par Value $0.0001 per share CRVS Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On June 15, 2023, Corvus Pharmaceuticals, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). Only stockholders of record at the close of business on April 18, 2023, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, there were 46,568,511 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 36,151,036 shares of the Company’s common stock were voted in person or by proxy for the three proposals set forth below, each of which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 28, 2023.

 

The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:

 

Proposal No. 1 — Election of Directors

 

The Company’s stockholders elected the Class I director nominees below to the Company’s Board of Directors to hold office until the 2026 Annual Meeting of Stockholders or until their respective successors are elected and qualified or appointed, or the earlier of their death, resignation or removal. 

 

Class I Director Nominees  Votes For  Votes Withheld  Broker Non-Votes
Richard A. Miller, M.D.   26,009,538    68,027    10,073,471 
Linda S. Grais, M.D. J.D.   25,210,111    867,454    10,073,471 

 

Proposal No. 2 — Ratification of Selection of Independent Registered Accounting Firm

 

The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLC as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. 

 

Votes For  Votes Against  Abstain
 35,873,795    104,973    172,268 

 

Proposal No. 3 —Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers

 

On a non-binding advisory basis, the Company’s stockholders approved the compensation of the Company’s named executive officers. 

 

Votes For  Votes Against  Abstain  Broker Non-Votes
 25,550,695    348,929    177,941    10,073,471 

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CORVUS PHARMACEUTICALS, INC.  
       
Date: June 20, 2023 By: /s/ Leiv Lea  
    Leiv Lea   
    Chief Financial Officer  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Corvus Pharmaceuticals Charts.
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Corvus Pharmaceuticals Charts.